VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that CEO David Domzalski will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 12:50 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that CEO David Domzalski will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 12:50 p.m. ET. The conference will provide an opportunity for investors to engage in 1-on-1 meetings with management. A webcast of the presentation is accessible via the provided link, and a replay will be available on the VYNE website for 90 days post-event. VYNE focuses on developing innovative therapies for immuno-inflammatory conditions, including its pipeline product FMX114 for atopic dermatitis.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was -5.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022. Management will also be available for 1-on-1 meetings with investors.
Virtual Presentation Details
| Date: | Tuesday, March 8th | |
| Time: | 12:50 p.m. ET | |
| Format: | Virtual Fireside Chat | |
| Webcast Link: | https://wsw.com/webcast/cowen108/vyne/2045898 |
The replay of the webcast will be available on the VYNE website for 90 days following the conference.
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors that the Company is developing for the potential treatment of immuno-inflammatory conditions.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.